Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04562246 · ClinicalTrials.gov registry record
SARS-CoV-2 IgG and IgM Serologic Assays
A clinical trial, sponsored by Henry Ford Health System.
- Completed
- Registry status
- 214
- Enrollment target
NCT04562246: Completed study, sponsored by Henry Ford Health System.
NCT04562246 is a clinical trial that has completed, run by Henry Ford Health System. The registered enrollment target is 214 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04562246 has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- 214 participants
- Enrollment target
Study Summary
The primary objective is to assess and validate the ability of the Beckman Coulter Access COVID-19 IgG and IgM assays to detect immunity in COVID-19 patients in the Henry Ford Hospital Health System.
Primary Outcome
Assessment of prevalence of antibodies to SARS-CoV-2 in subjects tested positive by RT-PCR
Interventions
- DIAGNOSTIC_TEST Serologic assays for antibodies to SARS-CoV-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2020-08-14 |
| Est. Completion | 2024-02-26 |
What the finished NCT04562246 record still lists
NCT04562246 is an observational study that tracks outcomes without assigning an intervention. The registered 214 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Serologic assays for antibodies to SARS-CoV-2 is the first listed.
NCT04562246 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04562246 about?
NCT04562246 is a clinical study titled "SARS-CoV-2 IgG and IgM Serologic Assays". The primary objective is to assess and validate the ability of the Beckman Coulter Access COVID-19 IgG and IgM assays to detect immunity in COVID-19 patients in the Henry Ford Hospital Health System.
What is the current status of trial NCT04562246?
This trial is currently completed. The enrollment target is 214 participants. The study started on 2020-08-14. Estimated completion is 2024-02-26.
What interventions are being tested in trial NCT04562246?
The interventions under investigation include: Serologic assays for antibodies to SARS-CoV-2 (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04562246?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04030507 · 214 participants · NA
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
- NCT04421248 · 214 participants · Phase 4
Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder
- NCT04667520 · 214 participants · NA
Testing a Lifestyle Physical Activity Intervention for Women With Depression in Alcohol Treatment
- NCT05418868 · 214 participants · Phase 1
A Study to Investigate Pharmacokinetics, Safety and Tolerability of Long-Acting Cabotegravir Plus Recombinant Human Hyaluronidase PH20 in Healthy Adult Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI